Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

What Was Tested

This randomized controlled trial paper looks at Exenatide.

Who Took Part

The abstract describes 336 patients taking part.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

In all, 272 patients completed the study.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The comparison arm used a placebo, so changes seen with Exenatide could be set against what happens without it.

The timeline in the abstract includes 4 weeks.

After 4 weeks of placebo, subjects self-administered 5 microg exenatide or placebo subcutaneously twice daily for 4 weeks followed by 5 or 10 microg exenatide, or placebo subcutaneously twice daily for 26 weeks.

All subjects continued metformin therapy.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 2, Exenatide, Glycated Hemoglobin, Hyperglycemia, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Exenatide in 336 patients over 4 weeks.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2005 (Diabetes care), a journal based in United States.

More context: the Exenatide compound page.